Low-dose IL-2 in Established T1D - The "PROREG" Study
Key facts
- Who runs it
- Jay S. Skyler
- Where
- Miami, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- Jun 2023
- Expected to end
- Dec 2028
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ILT-101 (Aldesleukin; IL-2)
- Treatment-Placebo Arm
- Placebo Arm
- Record updated
- 22 May 2024
- Why it stopped
- Funding withdrawal and COVID-19 environment.
Who can take part
- Age
- 8 years to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- 8-21 years of age
- T1D, demonstrated by at least one islet autoantibody
- T1D duration 4-12 months at the time of the first dose
- Peak stimulated C-peptide >0.2 nmol/L during a 4-hour MMTT
Who cannot take part
- Treatment with oral anti-diabetic agents
- Illnesses that would preclude use of low-dose IL-2
Where in United States
- Diabetes Research Institute, University of Miami Miller School of MedicineMiami, United States
About the trial
What the trial wants to find out
Randomized, controlled, double-blinded, multicenter, phase I/II clinical trial to evaluate the safety of low-dose IL-2 and determine whether low-dose IL-2 therapy for one year, can prevent further loss of beta-cell function in patients with established T1D, (primary outcome). The study will carefully examine various effects of low-dose IL-2 on the immune system in patients with T1D, including effects on Treg and other cell subsets, and disease-specific autoimmune responses.
The 3 groups in the trial
- Treatment ArmExisting treatment, for comparison
ILT-101 (Aldesleukin; IL-2), 0.5 million IU/m2 (up to a maximum of 1 million IU), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for two years.
Treatment: ILT-101 (Aldesleukin; IL-2)
- Treatment-Placebo ArmTreatment being tested
Participants in this group will receive study drug ILT-101 for one year, and then placebo for the second year.
Treatment: ILT-101 (Aldesleukin; IL-2) and Treatment-Placebo Arm
- PlaceboPlacebo, for comparison
Participants in this group will receive a placebo injection for two years.
Treatment: Placebo Arm
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double Blind, Phase I/II Trial of Low-Dose Interlekin-2 Immunotherapy in Established Type 1 Diabetes
- Record updated
- 22 May 2024